Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E183.09 EPS (ttm)0.76 Insider Own0.50% Shs Outstand225.32M Perf Week-3.03%
Market Cap31.35B Forward P/E20.28 EPS next Y6.86 Insider Trans-25.34% Shs Float224.01M Perf Month-20.20%
Income144.40M PEG10.10 EPS next Q1.14 Inst Own99.90% Short Float2.52% Perf Quarter-19.77%
Sales2.60B P/S12.04 EPS this Y156.70% Inst Trans-0.39% Short Ratio3.54 Perf Half Y-26.62%
Book/sh36.48 P/B3.81 EPS next Y31.51% ROA2.60% Target Price206.11 Perf Year-20.77%
Cash/sh6.47 P/C21.50 EPS next 5Y18.12% ROE3.90% 52W Range130.51 - 208.88 Perf YTD-27.05%
Dividend- P/FCF61.63 EPS past 5Y14.90% ROI19.50% 52W High-33.08% Beta0.93
Dividend %- Quick Ratio2.90 Sales past 5Y42.00% Gross Margin91.00% 52W Low7.11% ATR8.10
Employees2273 Current Ratio3.20 Sales Q/Q20.10% Oper. Margin24.70% RSI (14)32.76 Volatility6.58% 5.88%
OptionableYes Debt/Eq0.42 EPS Q/Q-192.00% Profit Margin8.90% Rel Volume1.51 Prev Close139.15
ShortableYes LT Debt/Eq0.40 EarningsFeb 03 BMO Payout0.00% Avg Volume1.60M Price139.79
Recom1.90 SMA20-8.25% SMA50-18.32% SMA200-19.62% Volume449,244 Change0.46%
Feb-04-16Reiterated UBS Buy $222 → $200
Feb-04-16Reiterated Barclays Equal Weight $202 → $175
Jan-20-16Initiated Credit Suisse Neutral
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $225
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Dec-11-15Reiterated Stifel Buy $250 → $245
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-14-15Downgrade Barclays Overweight → Equal Weight $220 → $205
Sep-01-15Initiated Raymond James Strong Buy $225
Jul-31-15Reiterated UBS Buy $220 → $223
Jul-31-15Reiterated Stifel Buy $239 → $257
Jul-31-15Reiterated Brean Capital Buy $213 → $221
Jul-27-15Resumed JP Morgan Overweight
May-07-15Upgrade Nomura Neutral → Buy
May-07-15Reiterated Brean Capital Buy $215 → $213
Jan-30-15Reiterated Stifel Buy $230 → $236
Jan-08-15Reiterated UBS Buy $220 → $213
Apr-25-14Reiterated Stifel Buy $219 → $220
Mar-11-14Reiterated UBS Buy $185 → $202
Mar-11-14Reiterated Stifel Buy $207 → $219
Feb-08-16 02:33PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
01:32PM  Alexion Pharmaceuticals' Big Top Foreshadows Big Drop
Feb-05-16 05:56PM  The Key Takeaways From Alexion Pharmaceuticals Inc.'s Earnings Release at Motley Fool
01:06PM  How to Play the Biotech Selloff at Barrons.com
10:32AM  Leerink Is Back On Board The Biotech Train
Feb-04-16 10:33AM  Alexion Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers
10:00AM  Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference Business Wire
08:15AM  Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3%
Feb-03-16 07:00PM  Lightning Round: This energy stock goes higher at CNBC +6.27%
04:53PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
01:27PM  Edited Transcript of ALXN earnings conference call or presentation 3-Feb-16 3:00pm GMT
01:20PM  Alexion Pharmaceuticals Rides the Earnings Roller Coaster at Barrons.com
10:50AM  Alexion Misses on Earnings and Revenues in Q4, Gives View
08:39AM  [$$] Alexion Pharmaceuticals Revenue Jumps, Profit Falls at The Wall Street Journal
08:00AM  Biotechnology Stocks Technical Snapshot -- Geron, ACADIA Pharma, Alexion Pharma, and Illumina Accesswire
07:55AM  Alexion (ALXN) Misses on Q4 Earnings and Revenues
07:37AM  Morning Movers: Alexion, Merck Drop on Earnings; Atwood Oceanics Gains at Barrons.com
07:07AM  Q4 2015 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open
06:57AM  Alexion tops 4Q profit forecasts
06:53AM  Alexion beats 4Q profit forecasts
06:30AM  Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016 Business Wire
Feb-01-16 03:57PM  Alexion Pharmaceuticals (ALXN) Stock Price Target Lowered at Credit Suisse at TheStreet
03:30PM  Is Alexion (ALXN) Likely to Disappoint this Earnings Season?
01:10PM  Will 2016 Be Alexion Pharmaceuticals Inc.'s Best Year Yet? at Motley Fool
Jan-30-16 08:05AM  Vertex Will Focus on Cystic Fibrosis Market in 2016
Jan-28-16 01:27PM  Facebook, Qualcomm, Alexion Seen Gaining From Patent Box Tax Reform
Jan-26-16 02:22PM  What Johnson & Johnson's Earnings Mean for Biotech Stocks at Barrons.com
12:06AM  Changes in BioMarins Valuation Multiples
Jan-21-16 02:41PM  Regeneron Pharmaceuticals Inc. Stock: Bargain or Rip-Off? at Motley Fool
Jan-20-16 10:00AM  Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016 Business Wire
06:12AM  Coverage initiated on Alexion Pharma by Credit Suisse
Jan-15-16 04:05PM  Researchers to Present New Data at ENDO 2016 Advancing the Understanding of Strensiq® (asfotase alfa) in Infants, Children and Adult Patients with Hypophosphatasia (HPP) Business Wire -5.15%
02:03PM  Why Ultragenyx Pharmaceuticals Skyrocketed in 2015 at Motley Fool
Jan-14-16 04:29PM  Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results at Investor's Business Daily +5.93%
04:28PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina
Jan-11-16 04:25PM  A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks at TheStreet
Jan-08-16 08:20AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 8, 2016
Jan-07-16 05:12PM  Gilead Leads 3 Drug Stocks With Top Fundamentals at Investor's Business Daily -5.27%
Jan-06-16 01:47PM  Goldman sees Facebook, Amazon, Netflix retaining star power -- but not Google at MarketWatch
Jan-04-16 12:02PM  Biotech: Here Comes Conservative Guidance at Barrons.com
10:00AM  Alexion to Present at the 34th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-03-16 10:43PM  Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals
Dec-25-15 08:06AM  Medivation Initiates Phase 2 Trial of MDV9300: Stock Rises 5.7%
Dec-24-15 12:44PM  [$$] Today's Top 5 Stock Picks: Focus on Earnings at Barrons.com
Dec-22-15 07:22AM  The Best 3 Biotech Stocks for 2016 at Motley Fool
Dec-21-15 06:31PM  Big Cap 20 Stocks Setting Up In Bases at Investor's Business Daily
01:05AM  Alexion Pharmaceuticals: A Top Stock of SPY
Dec-18-15 04:40PM  Profit Booking Hobbles the SPDR S&P Biotech ETFs Large-Caps on December 17
Dec-17-15 08:06AM  Medicines Company Announces Phase-1 Data on MDCO-216
Dec-15-15 02:21PM  The Biotechs With Market Moving Drug Pipelines
Dec-14-15 01:08PM  Alexion Led among the Large-Caps, IHF Large-Caps Outperform
Dec-13-15 01:35AM  Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences
Dec-12-15 12:01AM  [$$] Includes Alexion Pharmaceuticals, Alphabet, and Dow Chemical at Barrons.com
Dec-11-15 03:22PM  Alexion Continues to Rise on FDAs Approval of Kanuma
Dec-10-15 05:00PM  Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting Business Wire
10:35AM  Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals
08:18AM  Alexion CEO: We are thrilled with FDA approval
07:02AM  US Investors Turned to Safe Havens, Market Remained Volatile
06:37AM  Alexion to Highlight Innovative Rare Disease Portfolio at Investor Day Meeting Business Wire
Dec-09-15 03:35PM  Alexion (ALXN) Gains after Kanuma Receives FDA Approval
03:04PM  European Commission Approves Amgens BLINCYTO: Stock Rises 0.2%
10:17AM  Top 5 Healthcare Bets of World-Class Baker Bros. Advisors at Insider Monkey
Dec-08-15 04:22PM  Instant Analysis: Alexion Pharmaceuticals Inc Wins an Important FDA Approval at Motley Fool +5.34%
02:56PM  U.S. stocks slump as commodities drag on global markets
02:20PM  U.S. drug approvals hit record level as biotech stocks sag at bizjournals.com
02:18PM  Alexion Wins Third Drug Approval; Stock Rises at Investor's Business Daily
01:16PM  ALEXION PHARMACEUTICALS INC Financials
12:52PM  ADDING MULTIMEDIA FDA Approves Kanuma (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Business Wire
12:07PM  Alexion Tops IBBs Large-Caps on Release of New Research Data
10:57AM  FDA approves Alexion Pharma's enzyme-replacement therapy Reuters
08:23AM  How it All Plays Out - Research on LinkedIn, Micron Technology, Alexion Pharmaceuticals and Fitbit Accesswire
Dec-07-15 04:05PM  Data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Presented at ASH Annual Meeting Underscore Devastating Nature of PNH and Benefits of Soliris® (eculizumab) Treatment Business Wire
10:59AM  JAB Pays Year's Second-Highest Premium for Keurig at The Wall Street Journal
09:16AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : December 7, 2015
Dec-03-15 01:06PM  Alexions Share Price Is Volatile on Impending Kanuma Decision
10:40AM  Heres why data this weekend from Alnylam's blood disease drugs could be a big deal at bizjournals.com
09:06AM  Kanuma: An Innovative Enzyme Replacement Therapy for LAL-D
08:06AM  Ligand Pharmaceuticals Trades Above 100-Day Moving Average
07:00AM  True North, Following the Alexion Rare Disease Playbook, Nabs $40M at Forbes
Dec-02-15 07:00PM  Alexion's $550,000 bone drug too expensive for Britain Reuters
04:29PM  Kanuma Clinical Trials Demonstrate Its Efficacy in Treating LAL-D
04:29PM  Alexion Pharmaceuticals Will Soon See a Decision on Kanuma
Dec-01-15 11:15AM  5 Health Care Trades to Buy for December Breakouts at TheStreet
Nov-30-15 02:54AM  Is Alexion Pharmaceuticals, Inc. (ALXN) A Good Stock To Buy? at Insider Monkey
Nov-29-15 02:30PM  3 Under-the-Radar Stocks That Won't Stay Ignored for Long at TheStreet
Nov-25-15 09:53AM  EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Nov-23-15 02:41PM  Is JD.Com Inc (ADR) (JD) A Good Stock To Buy? at Insider Monkey
Nov-22-15 07:42AM  3 Biotech Stocks to Buy in December at Motley Fool
Nov-21-15 12:01AM  [$$] Biotech's Biggest Battle at Barrons.com
Nov-20-15 10:44AM  Hedge Funds Are Dumping Delta Air Lines, Inc. (DAL) at Insider Monkey
Nov-19-15 10:00AM  Alexion to Highlight Robust Rare Disease Pipeline at Investor Day Business Wire
Nov-16-15 01:43PM  These Biotech Stocks May Start Paying Dividends in 2016 at Motley Fool
Nov-13-15 12:30PM  Mariner Investment Groups Top Biotech Stock Picks For Q4 at Insider Monkey
Nov-12-15 05:33AM  Germany, U.S. in hot pursuit of "messenger" drug molecules
Nov-11-15 03:38PM  A Duo of Catalysts Sends Alexion Pharmaceuticals 13% Higher in October at Motley Fool
Nov-10-15 09:40AM  3 Beaten-Down Biotech Stocks to Buy Now at Kiplinger
08:05AM  Vertex Reported Its 3Q15 Earnings: Stock Rose 5%
07:05AM  Buy Amgen's Healthy Dividend, Hold for Its Growth Prescription at TheStreet
Nov-09-15 05:24AM  Amgen on the hunt for potential $10bn deal at Financial Times
Nov-07-15 12:30PM  Long-Term Follow-up Study Presented at ASN 2015 Supports Effectiveness of Soliris® (eculizumab) in Preventing Thrombotic Microangiopathy (TMA) Events in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Business Wire
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hallal DavidCEOFeb 08Sale138.053,946544,763173,026Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 08Sale138.082,633363,57748,501Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 08Sale138.071,474203,51844,704Feb 08 07:56 PM
BELL LEONARDDirectorFeb 08Sale138.0911,4741,584,442746,192Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 08Sale138.052,665367,91134,054Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale138.07942130,06629,937Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale138.07778107,41930,348Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 08Sale138.091,966271,48140,785Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 08Sale137.613,890535,316171,862Feb 08 07:56 PM
Hallal DavidCEOFeb 05Sale141.636,722952,043176,972Feb 08 07:57 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 05Sale143.021,051150,31414,215Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 05Sale143.451,969282,44751,134Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 05Sale143.481,970282,66146,178Feb 08 07:56 PM
BELL LEONARDDirectorFeb 05Sale143.122,136305,702757,666Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 05Sale141.761,993282,53836,719Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale143.14997142,70830,879Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale143.232,080297,91931,126Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 05Sale141.562,005283,82342,751Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 05Sale143.501,954280,404175,752Feb 08 07:56 PM
Hallal DavidCEOFeb 04Sale143.8362990,469142,558Feb 08 07:57 PM
BELL LEONARDDirectorFeb 04Sale143.832,262325,338746,997Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale143.8420729,77426,949Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 04Sale143.8416924,30925,747Feb 08 07:57 PM
Sinha VikasEVP & CFOFeb 04Sale143.83703101,116165,943Feb 08 07:56 PM
BELL LEONARDDirectorDec 29Option Exercise22.9028,968663,367778,227Dec 29 05:03 PM
BELL LEONARDDirectorDec 29Sale190.8028,9685,526,983749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Option Exercise22.904009,160749,659Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Sale190.1540076,060749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Option Exercise22.905,632128,973754,891Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Sale190.005,6321,070,080749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 17Option Exercise22.9070,0001,603,000819,259Dec 21 05:43 PM
BELL LEONARDDirectorDec 17Sale187.6970,00013,137,985749,259Dec 21 05:43 PM
NORBY R DOUGLASDirectorDec 11Sale187.7145,4428,530,12432,481Dec 15 05:36 PM
Moriarty John BEVP & General CounselDec 11Sale182.73943172,31141,340Dec 15 05:35 PM
Veneman Ann MDirectorDec 11Sale187.48895167,7953,252Dec 15 05:36 PM
BELL LEONARDDirectorDec 11Sale187.5621,3193,998,527727,940Dec 15 05:36 PM
Islam SaqibEVP, Chief Strat & Port. Off.Dec 08Sale190.00950180,50036,385Dec 08 07:36 PM
BELL LEONARDDirectorDec 08Sale188.2070,00013,173,840849,088Dec 08 07:36 PM
BELL LEONARDDirectorNov 25Option Exercise22.9035,000801,500954,088Nov 30 05:42 PM
BELL LEONARDDirectorNov 25Sale181.8935,0006,366,288919,088Nov 30 05:42 PM
Thiel CarstenEVP, Chief Commercial OfficerNov 10Sale173.343,000520,02028,018Nov 12 06:25 PM
PARVEN ALVIN SDirectorNov 02Sale178.73895159,9634,645Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Nov 02Sale180.00975175,50037,335Nov 04 05:29 PM
BELL LEONARDDirectorNov 02Sale180.1235,0006,304,200919,088Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Oct 26Sale168.441,558262,43038,310Oct 29 05:17 PM
Thiel CarstenSVP, EMEA & Asia PacificSep 10Sale169.18812137,37129,018Sep 10 08:45 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale179.5536665,7156,464Sep 10 08:45 PM
BELL LEONARDDirectorSep 09Sale180.101,050189,105919,088Sep 10 08:46 PM
O'Neill JulieEVP. Global OperationsSep 02Sale171.76647111,12921,443Sep 10 08:46 PM
Carmichael ClareEVP, Chief HR OfficerSep 01Sale168.6230551,42927,156Sep 03 07:08 PM
Hallal DavidCEOAug 07Sale190.0132962,513143,187Aug 11 05:53 PM
Carmichael ClareEVP, Chief HR OfficerAug 07Sale190.0116330,97227,461Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 07Sale190.0113525,65142,283Aug 11 05:53 PM
BELL LEONARDDirectorAug 07Sale190.011,003190,580919,088Aug 11 05:53 PM
Moriarty John BEVP & General CounselAug 05Option Exercise92.6520,0001,853,00042,428Aug 05 06:08 PM
Moriarty John BEVP & General CounselAug 05Sale198.4410,0101,986,37732,418Aug 05 06:08 PM
Carmichael ClareEVP, Chief HR OfficerAug 04Sale196.5218536,35627,624Aug 05 06:09 PM
Hallal DavidCEOAug 04Sale196.52612120,270143,516Aug 05 06:09 PM
BELL LEONARDDirectorAug 04Sale196.522,200432,344920,091Aug 05 06:08 PM
Sinha VikasEVP & CFOAug 04Sale196.52675132,651166,646Aug 05 06:08 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Option Exercise130.2943,5005,667,48876,393Aug 05 06:09 PM
MACKAY MARTINEVP & Global Head of R&DAug 03Sale196.5243,5008,548,41832,893Aug 05 06:09 PM
BELL LEONARDDirectorJun 18Sale179.6327,8355,000,001922,291Jun 19 07:09 PM
Moriarty John BEVP & General CounselJun 11Sale170.00914155,38032,428Jun 12 06:26 PM
Monnet DominiqueSVP, Chief Marketing OfficerMay 20Sale162.4025641,5748,787May 22 05:30 PM
MACKAY MARTINEVP & Global Head of R&DMay 14Sale160.334,056650,29832,893May 22 05:30 PM
Islam SaqibEVP, Chief Strat & Port. Off.Apr 27Sale181.576,0321,095,23039,868Apr 30 09:45 PM
BELL LEONARDCEOMar 19Sale188.0715,9523,000,093949,426Mar 20 05:02 PM
MACKAY MARTINEVP & Global Head of R&DMar 02Sale180.3437066,72636,949Mar 03 09:13 PM
Sinha VikasEVP & CFOMar 02Sale180.3448787,826167,321Mar 03 09:13 PM
O'Neill JulieEVP. Global OperationsMar 02Sale180.346,5651,183,93222,090Mar 03 09:13 PM
Islam SaqibEVP, Chief Strat & Port. Off.Mar 02Sale180.3422841,11839,432Mar 03 09:12 PM
Moriarty John BEVP & General CounselMar 02Sale180.3428050,49533,342Mar 03 09:13 PM
BELL LEONARDCEOMar 02Sale180.341,230221,818965,378Mar 03 09:11 PM
Hallal DavidChief Operating OfficerMar 02Sale180.34730131,648132,858Mar 03 09:11 PM
Carmichael ClareEVP, Chief HR OfficerMar 02Sale180.34706127,32027,809Mar 03 09:12 PM
MACKAY MARTINEVP & Global Head of R&DFeb 10Sale173.973,897677,95632,219Feb 12 09:07 PM
Monnet DominiqueSVP, Chief Marketing OfficerFeb 10Sale171.1532555,6245,213Feb 12 09:07 PM
O'Neill JulieEVP. Global OperationsFeb 10Sale171.15795136,06423,555Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 10Sale171.151,985339,733162,708Feb 12 09:08 PM
BELL LEONARDCEOFeb 10Sale171.155,740982,401944,308Feb 12 09:06 PM
Hallal DavidChief Operating OfficerFeb 10Sale171.151,980338,877124,033Feb 12 09:06 PM
Carmichael ClareEVP, Chief HR OfficerFeb 10Sale171.151,490255,01421,670Feb 12 09:06 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 10Sale171.151,500256,72534,560Feb 12 09:06 PM
Moriarty John BEVP & General CounselFeb 10Sale171.151,490255,01426,777Feb 12 09:07 PM